|
業務類別
|
Biotechnology |
|
業務概覽
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
| 公司地址
| 490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 857 760-0900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.neumoratx.com |
| 員工數量
| 110 |
| Mr. Michael Lee Milligan |
Principal Accounting Officer and Chief Financial Officer |
-- |
13/02/2025 |
| Ms. Carol Suh |
Chief Strategy Officer |
-- |
13/02/2025 |
| Dr. Joshua Pinto, PhD |
President |
-- |
13/02/2025 |
| Dr. Daljit Singh Aurora, Pharm.D. |
Chief Operating and Development Officer |
美元 496.79K |
13/02/2025 |
| Mr. Paul L. Berns |
Executive Chairman of the Board and Chief Executive Officer |
美元 470.00K |
13/02/2025 |
| Mr. Jason G. Duncan |
Chief Legal and Administrative Officer |
-- |
13/02/2025 |
|
|
| Mr. David Piacquad |
Independent Director |
29/04/2025 |
| Ms. Kristina M. Burow |
Independent Director |
29/04/2025 |
| Mr. Paul L. Berns |
Executive Chairman of the Board and Chief Executive Officer |
13/02/2025 |
| Mr. Matthew K. Fust |
Independent Director |
29/04/2025 |
| Mr. Alaa Halawa |
Independent Director |
29/04/2025 |
| Dr. Maykin Ho, PhD |
Independent Director |
29/04/2025 |
|
|
|
|
